Sodium phenylbutyrate
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Medium-chain Acyl-CoA Dehydrogenase Deficiency
Conditions
Medium-chain Acyl-CoA Dehydrogenase Deficiency
Trial Timeline
Jun 30, 2025 → Jul 1, 2027
NCT ID
NCT06773026About Sodium phenylbutyrate
Sodium phenylbutyrate is a phase 2 stage product being developed by Zevra Therapeutics for Medium-chain Acyl-CoA Dehydrogenase Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06773026. Target conditions include Medium-chain Acyl-CoA Dehydrogenase Deficiency.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07125066 | Phase 1 | Recruiting |
| NCT06773026 | Phase 2 | Recruiting |
Competing Products
2 competing products in Medium-chain Acyl-CoA Dehydrogenase Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 2 | 47 |